9 augustus 2021: Apacbiotech

Apceden is een combinatie van dendritische celtherapie met een vaccin en is in India goedgekeurd om te gebruiken bij kankerpatiënten met solide tumoren. In een van hun studies bij kankerpatiënten met vergevorderde uitgezaaide kanker die alleen nog palliatief werden behandeld met beste zorg werd de uiteindelijke overall overleving verdubbeld van een half jaar naar een jaar. 

Hier enkele studies in willekeurige volgorde en klik op de titels voor de studierapporten in PDF opgemaakt:

A retrospective analysis comparing APCEDENR dendritic cell immunotherapy with best supportive care in refractory cancer

Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care


Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN)

Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN ® (dendritic cell‐based vaccine): a case report


Op de website van de producent van Apceden staan nog enkele andere studies en ook uitgelegd hoe hun vorm van immuuntherapie werkt.

Op deze pagina staat hun contactadres en contactgegevens.

Hier wat referenties:

References

1. Majchrzak, E. , Szybiak B., Wegner A., Pienkowski P., Pazdrowski J., Luczewski L., et al. 2014. Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literatureRadiol. Oncol. 48:1–10. [PMC free article] [PubMed[]
2. Cohan, D. M. , Popat S., Kaplan S. E., Rigual N., Loree T., and Hicks W. L. Jr. 2009. Oropharyngeal cancer: current understanding and managementCurr. Opin. Otolaryngol. Head Neck Surg. 17:88–94. [PubMed[]
3. Chi, A. C. , Day T. A., and Neville B. W.. 2015. Oral cavity and oropharyngeal squamous cell carcinoma—an updateCA Cancer J. Clin. 65:401–421. [PubMed[]
4. Huang, C. J. , Chao K. S., Tsai J., Simpson J. R., Haughey B., Spector G. J., et al. 2001. Cancer of retromolar trigone: long‐term radiation therapy outcomeHead Neck 23:758–763. [PubMed[]
5. Rachel, J. R. , Kumar N. S., and Jain N. K.. 2011. Basaloid squamous cell carcinoma of retromolar trigone: a case report with review of literatureJ. Oral Maxillofac. Pathol. 15:192–196. [PMC free article] [PubMed[]
6. Faisal, M. , Abbas T., Khaleeq U., Adeel M., Anwer A. W., Hussain R., et al. 2017. Treatment outcomes of rare retromolar trigone squamous cell carcinoma using combined modalitiesCureus 9:e1203. [PMC free article] [PubMed[]
7. Figdor, C. G. , de Vries I. J., Lesterhuis W. J., and Melief C. J.. 2004. Dendritic cell immunotherapy: mapping the wayNat. Med. 10:475–480. [PubMed[]
8. O'Neill, D. W. , Adams S., and Bhardwaj N.. 2004. Manipulating dendritic cell biology for the active immunotherapy of cancerBlood 104:2235–2246. [PubMed[]
9. Ackerman, A. L. , Kyritsis C., Tampe R., and Cresswell P.. 2003. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigensProc. Natl. Acad. Sci. U S A 100:12889–12894. [PMC free article] [PubMed[]
10. Dhodapkar, M. V. , Steinman R. M., Sapp M., Desai H., Fossella C., Krasovsky J., et al. 1999. Rapid generation of broad T‐cell immunity in humans after a single injection of mature dendritic cellsJ. Clin. Invest. 104:173–180. [PMC free article] [PubMed[]
11. Mackensen, A. , Herbst B., Chen J. L., Kohler G., Noppen C., Herr W., et al. 2000. Phase I study in melanoma patients of a vaccine with peptide‐pulsed dendritic cells generated in vitro from CD34 (+) hematopoietic progenitor cellsInt. J. Cancer 86:385–392. [PubMed[]
12. Banchereau, J. , Palucka A. K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., et al. 2001. Immune and clinical responses in patients with metastatic melanoma to CD34 (+) progenitor‐derived dendritic cell vaccineCancer Res. 61:6451–6458. [PubMed[]
13. Wojas‐Krawczyk, K. , Krawczyk P., Buczkowski J., Walkowska A., Jankowska O., Czekajska‐Chehab E., et al. 2012. Immunotherapy of lung adenocarcinoma patient with Peptide‐pulsed dendritic cells: a case reportArch. Immunol. Ther. Exp. (Warsz) 60:69–77. [PubMed[]
14. Liau, L. M. , Prins R. M., Kiertscher S. M., Odesa S. K., Kremen T. J., Giovannone A. J., et al. 2005. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T‐cell responses modulated by the local central nervous system tumor microenvironmentClin. Cancer Res. 11:5515–5525. [PubMed[]
15. Bapsy, P. P. , Sharan B., Kumar C., Das R. P., Rangarajan B., Jain M., et al. 2014. Open‐label, multi‐center, non‐randomized, single‐arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive careCytotherapy 16:234–244. [PubMed[]
16. Halpert, M. M. , Konduri V., Liang D., Chen Y., Wing J. B., Paust S., et al. 2016. Dendritic cell‐secreted cytotoxic T‐lymphocyte‐associated protein‐4 regulates the T‐cell response by downmodulating bystander surface B7Stem Cells Dev. 25:774–787. [PMC free article] [PubMed[]
17. Faria, S. S. , Fernandes P. C. Jr, Silva M. J. B., Lima V. C., Fontes W., Freitas‐Junior R., et al. 2016. The neutrophil‐to‐lymphocyte ratio: a narrative reviewEcancermedicalscience 10:702. [PMC free article] [PubMed[]
18. Piciucchi, M. , Stigliano S., Archibugi L., Zerboni G., Signoretti M., Barucca V., et al. 2017. The neutrophil/lymphocyte ratio at diagnosis is significantly associated with survival in metastatic pancreatic cancer patientsInt. J. Mol. Sci. 18:730. [PMC free article] [PubMed[]
19. Templeton, A. J. , Knox J. J., Lin X., Simantov R., Xie W., Lawrence N., et al. 2016. Change in neutrophil‐to‐lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacyEur. Urol. 70:358–364. [PubMed[]
20. Palucka, K. , and Banchereau J.. 2013. Dendritic‐cell‐based therapeutic cancer vaccinesImmunity 39:38–48. [PMC free article] [PubMed[]
21. Schuler‐Thurner, B. , Schultz E. S., Berger T. G., Weinlich G., Ebner S., Woerl P., et al. 2002. Rapid induction of tumor‐specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide‐loaded monocyte‐derived dendritic cellsJ. Exp. Med. 195:1279–1288. [PMC free article] [PubMed[]
22. Boudewijns, S. , Westdorp H., Koornstra R. H., Aarntzen E. H., Schreibelt G., Creemers J. H., et al. 2016. Immune‐related adverse events of dendritic cell vaccination correlate with immunologic and clinical outcome in stage III and IV melanoma patientsJ. Immunother. 39:241–248. [PMC free article] [PubMed[]
23. Hoos, A. 2012. Evolution of end points for cancer immunotherapy trialsAnn. Oncol. 23(Suppl. 8):viii47–viii52. [PubMed[]
24. Wolchok, J. D. , Hoos A., O'Day S., Weber J. S., Hamid O., Lebbe C., et al. 2009. Guidelines for the evaluation of immune therapy activity in solid tumors: immune‐related response criteriaClin. Cancer Res. 15:7412–7420. [PubMed[]
25. Chiou, V. L. , and Burotto M.. 2015. Pseudoprogression and Immune‐Related Response in Solid TumorsJ. Clin. Oncol. 33:3541–3543. [PMC free article] [PubMed[]
26. Ferrucci, P. F. , Gandini S., Battaglia A., Alfieri S., Di Giacomo A. M., Giannarelli D., et al. 2015. Baseline neutrophil‐to‐lymphocyte ratio is associated with outcome of ipilimumab treated Metastatic melanoma patientsBr. J. Cancer 112:1904–1910. [PMC free article] [PubMed[]

Articles from Clinical Case Reports are provided here courtesy of Wiley-Blackwell
 

Plaats een reactie ...

Reageer op "Apceden, een gepersonaliseerd vaccin toegevoegd aan dendritische celtherapie geeft opvallend goede resultaten bij solide tumoren, waaronder ook prostaatkanker"


Gerelateerde artikelen
 

Gerelateerde artikelen

Darmschimmels - darmbacterien >> Apceden, een gepersonaliseerd >> Immuungerelateerde ernstige >> Nivolumab na neoadjuvante >> Idecabtagene vicleucel (Abecma) >> Hoge tumormutatiebelasting >> CIMAvax-EGF vaccin geeft uitstekende >> Gentherapie voor ernstige >> Immuuntherapie alleen of in >> NLR meting - veranderende >>